北陆药业主要从事化学药品和中成药的研发、生产和销售。公司产品涵盖对比剂、降糖药、抗焦虑中药 等多个治疗领域。2025年上半年，公司实现营业收入5.84亿元，同比增长23.27%；实现归母净利润 2996.69万元，同比增长53.35%。其中，对比剂产品销售收入3.39亿元，同比增长21.11%；中药制剂销 售收入1.18亿元，同比增长32.84%。 截至2025年8月26日收盘，北陆药业股价报10.09元，较前一交易日下跌0.21元，跌幅2.04%。当日成交 量为396046手，成交金额达4.04亿元。 从资金流向来看，北陆药业8月26日主力资金净流出4950.70万元，近五日累计净流出20162.52万元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 ...

Group 1: Business Performance and Revenue - In 2024, the company achieved sales revenue of CNY 58,804.95 million for contrast agents, a year-on-year increase of 9.87% [1] - Sales revenue for hypoglycemic products reached CNY 12,598.34 million, growing by 33.24% year-on-year [1] - The company reported a decline in raw material sales revenue to CNY 9,003.14 million, down by 20.83% [1] - Sales revenue for traditional Chinese medicine preparations was CNY 16,844.68 million, reflecting a year-on-year growth of 19.65% [1] - The company’s overseas revenue for 2024 was CNY 13,216.14 million, marking a 15.02% increase [4] Group 2: Strategic Developments - The company continues to implement a "chemical + traditional Chinese medicine" dual-driven strategy, focusing on contrast agents, hypoglycemic drugs, and central nervous system traditional Chinese medicine [1] - The construction of the Cangzhou Phase III raw material production project has been completed, enhancing the production capacity for gadolinium and iodine contrast agents [2] - The Bozhou production base is progressing, with the first phase expected to start trial production and process validation within the year [3] Group 3: Market Expansion and Product Development - The company is expanding its market presence internationally, with successful exports of contrast agents and raw materials to South America, Africa, and Asia [4] - The company’s subsidiary, Haichang Pharmaceutical, is one of the few domestic producers with iodine contrast agent production qualifications, with an annual capacity of 1,000 tons [2] - The "MERCURY non-invasive blood test" technology developed by the affiliated company, Shihe Gene, allows for the screening of nine types of cancer from a single blood sample [7]